IL34930A - Haemolytic assay system - Google Patents
Haemolytic assay systemInfo
- Publication number
- IL34930A IL34930A IL34930A IL3493070A IL34930A IL 34930 A IL34930 A IL 34930A IL 34930 A IL34930 A IL 34930A IL 3493070 A IL3493070 A IL 3493070A IL 34930 A IL34930 A IL 34930A
- Authority
- IL
- Israel
- Prior art keywords
- complement
- agar
- gel
- hemolysin
- antigen
- Prior art date
Links
- 230000002949 hemolytic effect Effects 0.000 title description 6
- 238000003556 assay Methods 0.000 title description 2
- 230000000295 complement effect Effects 0.000 claims description 66
- 239000000427 antigen Substances 0.000 claims description 40
- 108091007433 antigens Proteins 0.000 claims description 40
- 102000036639 antigens Human genes 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 29
- 239000000499 gel Substances 0.000 claims description 28
- 210000003743 erythrocyte Anatomy 0.000 claims description 26
- 229920001817 Agar Polymers 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 108010006464 Hemolysin Proteins Proteins 0.000 claims description 12
- 239000003228 hemolysin Substances 0.000 claims description 12
- 239000013060 biological fluid Substances 0.000 claims description 11
- 238000009792 diffusion process Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000008272 agar Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 5
- 241001494479 Pecora Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 230000009089 cytolysis Effects 0.000 description 10
- 239000003349 gelling agent Substances 0.000 description 9
- 230000000951 immunodiffusion Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 235000010419 agar Nutrition 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000223205 Coccidioides immitis Species 0.000 description 2
- 206010014979 Epidemic typhus Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 241000606651 Rickettsiales Species 0.000 description 2
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000003486 coccidioidomycosis Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000012817 gel-diffusion technique Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920002972 Acrylic fiber Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000011874 heated mixture Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
ηι»ο·>ιοη mp a nmya Haemolytic aaaay system BAXTER LABORATORIES, INC. 0.33194 This invention relates to a method for the determination of nntibodies in biological fluids and, more particularly, to a diffusion method for the quantitative or semi-quantitative determination of complement fixing antibodies in blood serum.
Antibodies are complex protein substances present in blood serum, some of which are known to protect against infectious agents (bacteria and viruses) or to neutralize toxins. These substances play an important part in the immunization against microbes and toxins. They cause agglomeration or destruction of cells, or precipitation of proteins in what is generally referred to as an antigen-antibody reaction.
Various techniques have been developed heretofor for the determination of antibodies or for the measurement of antigen- antibody reactions. Like other proteins, the presence of antibodies can be demonstrated by conventional methods of fractional precipitation, electrophoresis, ultracentrifugation, and other such physico-chemical or analytical methods.
One procedure that has been found to be a particularly useful analytical and diagnostic tool for the determination of antibodies or antigens is the technique known as 'Immunodiffusion". Immunodiffusion involves a reaction, e. g. , between an antigen and an antibody, in semi-solid gel media, generally an agar gel. Both reactants are initially soluble in the medium, but the subsequent reaction product or complex of the antigen- antibody reaction is insoluble and results in the formation of a visible precipitin arc that can be observed visually with the eye or photographically. The agar gel diffusion method for the study of precipitation reactions has come to be known ; I H the Ouchterlony technique in view of the early and intensive work in the field by Orjan Ouchterlony, "Handbook of Immunodiffusion and Immunoelectrophoresis", Ann Arbor Science Publishers, Inc. , Ann Arbor, Mich. (1968).
A special adaptation of immunodiffusion, known as "Immunoelectrophoresis", employs the combined technique of separation of mixtures of antigens by agar gel electrophoresis and subsequent antigen- antibody reactions resulting in the formation of Ouchterlony, or precipitin, arcs.
Another adaptation of immunodiffusion, known as "radial immunodiffusion", employs an agar gel system containing the antibody in the agar gel and the antigen in the test serum diffuses radially from a circular reservoir or well to form a radial precipitin zone in the agar gel.
The aforesaid general techniques of immunodiffusion are summarized by Lou and Shanbrom, J. Am. Med. Ass'n. , Vol. 200, pp. 161 and 323 (1966).
In the study of certain antigen- antibody reactions it has been found that completion of reaction requires the aid of a special agent, present in normal sera, known as complement. In these serological reactions two stages have been distinguished. The first stage is the specific union between antibodies and the substrate, which is then followed by a second stage involving visible changes such as flocculation or lysis. Thus it is known that after fixation of lysine to cells, addition of complement is necessary to bring about dissolution.
The characteristic of complement to be bound by the aggregates formed through the interaction of antigens and antibodies is the basis for a commonly used serological test referred to as the complement-fixation reaction. In this test, the antigen and antibody to be tested are mixed with a source of complement and, after incubation, hemolytic immune serum and corresponding red cells are added. If an immunological reaction takes place in the first stage, complement is fixed and removed from the solution and hemolysis is prevented, completely or in part, according to the intensity of the reaction.
Immunodiffusion techniques as described hereinbefore have recently been applied to studies on serological hemolysis and, particularly, to studies on the complement-fixation test. Thus, Milgrom et al. , Vox Sang. , Vol. 8, pp. 537-48 (1963) and J. Immunol. , Vol. 96, pp. 415-23 (1966), have described agar gel diffusion procedures for studies on lysis of sheep red blood cells, induced by rabbit anti-sheep hemolysin and guinea pig complement. In single diffusion procedures, hemolytic zones were studied which were formed by complement diffusing into agar containing sheep red blood cells and hemolysin as well as hemolytic zones formed by hemolysin diffusing into agar containing sheep red blood cells and complement. In double diffusion procedures, complement and hemolysin were allowed to diffuse against each other in agar containing sheep erythrocytes only. These diffusion procedures were particularly applied to the study of )( G and ^ M hemolytic antibodies.
It is an object of the present invention to provide a new and improved method for the determination of complement fixing antibodies in biological fluids.
It is another object of this invention to provide a single diffusion method for the quantitative or semi -quantitative determination of complement fixing antibodies, in blood serum.
It is a further object of this invention to provide a rapid and convenient method for the detection and quantitation of complement fixing antibodies in a patient's serum as a useful adjunct in the diagnosis of diseases known to produce complement fixing antibodies, for example, various microbial, viral, bacterial, rickettsial, protozoan, fungal and helminthal infections.
Other objects and advantages will be apparent to the person skilled in the art after reading the disclosure hereof.
In accordance with the present invention, predetermined amounts of complement and a complement fixing antigen are admixed with an antibody- containing biological fluid in predetermined proportions and the mixture is reacted with a known amount of hemolysin-sensitized erythrocytes in a semi-solid solid gel medium for a predetermined period of time.
In this procedure if complement is not fixed (negative test), a clear, visible radial diffusion zone of lysis appears, whereas if complement and antigen are fixed to the antibody (positive test), no lysis occurs. In a positive test the diameter of the diffusion zone is inversely proportional to the complement fixing antibody titer.
In a preferred method of the invention, the hemolysin-sensitized erythrocytes are homogeneously dispersed in a semi-solid gel medium on a plate and the mixture of complement, complement fixing antigen, and antibody-containing biological fluid is introduced into the semisolid gel medium through open wells or cylindrical holes punched or otherwise formed in the gel. In this procedure, the diffusion zone of lysis will form at the interface of the gel and the fluid sample introduced through the well.
Preferably, a mixture of complement fixing antigen and an excess of complement is added to the unknown sample of blood serum or other biological fluid to be determined for complement fixing antibodies and the resulting mixture is added to the open wells by means of a capillary pipette or similar device. The plate is then incubated at a temperature of from about 0° to about 50°C for about 30 minutes to about 48 hours, and preferably at about 30°-40°C for about 2-6 hours. During this incubation, a clear, radial diffusion zone of lysis will appear in a negative test.
The amounts and proportions of antigen, complement and unknown sample used in the method of this invention can vary widely so long as they are predetermined and can be compared with control or known samples. In an illustrative example, excellent results are obtained when one volume of antigen, one volume of complement which has been diluted 1 :5 and one volume of unknown blood serum are incubated at about 0°- 10°C for about 30 minutes to about 18 hours.
In the preparation of the gel medium, any conventional gelling agent can be used, for example, gelatin, pectin, silica gel, starch. polysaccharides from seaweeds such as agar, algin and carrageenin, synthetic polymeric gelling agents such as the cross -linked poly- acrylamide disclosed in U. S. Patent 3, 046, 201, the modified celluloses disclosed in U. S. Patent 3, 360, 440 and the like materials.
The gelling agent preferably has the physical properties characterizing agar-agar insofar as it is readily dispersible in water and capable of forming an essentially clear hydrogel of sufficient rigidity so that the receptacle or plate containing the gel can be inverted without danger of the gel falling out.
Agar is the preferred gelling agent employed in the gel medium of the present invention. This gelling agent is generally used at a concentration of from about 0. 1% to about 5% by weight of gel medium, and preferably at a concentration of about 1. 5% by weight of the gel medium.
The gel medium is conveniently prepared by dissolving the gelling agent in hot water, adding predetermined amounts of hemolysin-sensitized erythrocytes, mixing thoroughly, and pouring into a low-sided flat receptacle (herein also referred to as a plate) in an amount appropriate for the size of the plate. The hemolysin-sensitized erythrocytes are generally used at a concentration of from about 0. 05% to about 5% by weight of the gel medium, and preferably at a concentration of about 0. 5% by weight of the gel medium. Preferably, equal volumes of solutions of the gelling agent and the hemolysin-sensitized erythrocytes are used in preparing the gel medium. The mixture of the gelling agent and hemolysin-sensitized erythrocytes is then allowed to gel, and wells or cylindrical holes approximately 1 to 10 millimeters in diameter are punched or otherwise formed in the gel.
The method of this ihvention can be used for the determination of antibodies which will react with antigens in a complement-fixation reaction. Thus, it can be used to determine the antibodies to various bacterial , fungal, viral, parasitic and rickettsial antigens. An example of a suitable complement fixing antigen is the Kolmer antigen described by Kolmer et_al. , J. Vener. Pis. Inform. , Vol. 29, pp. 166-72 (1948). Other illustrative complement fixing antigens are the Rocky Mountain spotted fever, epidemic typhus, mumps virus, and coccidioidomycosis antigens.
The complement used in this invention can be obtained from any well-known source of complement. For example, a commercially available lyophilized whole guinea pig serum reconstituted to its original volume can be used. Preferably, the reconstituted serum is diluted 1 :5 before use.
A suitable complement can also be conveniently prepared by collecting whole guinea pig blood and allowing it to clot. The red blood cells are removed by centrifugation and the retained serum is frozen and dried and then reconstituted before use.
Preferably, the dried complement is reconstituted with Kolmer saline solution, which can be prepared by dissolving 8. 5 grams NaCl, 0. 082 grams MgCl2* 6H2O and 0. 040 grams CaClg* 2H2O in one liter distilled water.
A small amount of preservative, for example, about 0. 01% sodium azide, is preferably added to the complement prior to drying.
Human, rabbit and other species of animals can also be used as sources of complement for use in the present invention.
The hemolysin-sensitized erythrocytes used in this invention are preferably hemolysin-sensitized sheep red blood cells. The latter cells are suspended in Kolmer saline solution at a concentration of about 1% to 5%, and preferably at about 2% by volume, and then sensitized with sheep cell hemolysin.
The sheep red cells can be hemolysin-sensitized as follows : Sheep cell hemolysin is diluted with from about 10 to about 100, and preferably about 19, volumes of Kolmer saline solution. To one volume of this hemolysin dilution is added about one volume of sheep red blood cells, preferably in a 2% suspension as described above.
The sheep cell hemolysin and sheep red blood cells are mixed at o o o about 0 to 30 C, and preferably at about 25 C, for about ten minutes, whereby the sheep red cells became sensitized to the hemolysin.
Rabbit serum or serum of other animal species having antibodies to sheep red blood cells can be used as the sheep cell hemolysin in this procedure.
The gel plate containing hemolysin-sensitized erythrocytes can be overlaid with a protective membrane, packaged by various means, and thereby made conveniently available for subsequent use in the determination of complement fixing antibody activity by hos¬ pitals, laboratories and other agencies and persons having need for a simplified, yet accurate, determination of complement fixing activity in blood plasma samples. The packages for these plates can be, for example, plastic film or metal foil bags, pouches, and the like, preferably sterilized and sealed to prevent the admission of air, moisture, dirt and other contaminating materials. Suitable metal foil can be fabricated, for example, from aluminum and like metals; suitable plastic film can be fabricated, for example, from vinyl chloride and vinylidiene chloride copolymers, polyvinyl chloride, polyvinyl alcohol, polyethylene, polypropylene, polystyrene, polycarbonates, polyamides, cellulose acetate and propionate, cellulose triacetate, cellulose acetate butyrate, ethyl cellulose, fluorocarbons, acrylic plastics such as acrylates and methacrylates, and polyesters such as, for example, polyesters formed by condensation reactions between ethylene glycol and terephthalic acid.
The gel plates obtaining the hemolysin-sensitized erythrocytes can also be packaged in combination with complement fixing antigens, complement and control samples, as well as with capillary tubes and other components for making the complete complement fixing assay.
The following examples will further illustrate the invention although the invention is not limited to these specific examples. All parte and percentages herein are on a weight basis unless otherwise specified.
Example 1 Hemolysin-sensitized erythrocytes are suspended in a semisolid gel medium as follows : Sheep cell hemolysin is diluted 1 :20 with Kolmer saline solution and then mixed with an equal volume of sheep red cells. This mixture is then mixed with an equal part by volume of a heated aqueous solution "' of 3. 0% Difco Noble Agar. The heated mixture is then poured into a plate of approximately 3" x l" x 1 /4" deep and allowed to gel. Six wells, each having a diameter of 2, mm. and being equidistantly spaced apart, are then punched into the gel.
The above prepared test plate is then used for the determination of complement fixing antibodies to Kolmer antigen as follows : One part by volume of Kolmer antigen is first mixed with an equal volume of complement and then with an equal volume of a blood serum sample in a test tube and held at 5°C for one hour. The complement is a reconstituted guinea pig complement diluted 1 :5 with Kolmer saline solution. The mixture is then added to a well in the o plate and incubated at 37 C for four hours. At the end of the incubation period, a clear, visible radial diffusion zone of lysis appears in a negative test in which the complement is not fixed, whereas no lysis or substantially less lysis appears in a positive test in which complement and the Kolmer antigen are fixed to the antibody in the blood serum sample.
In order to provide a quantitative or semi-quantitative determination of the complement fixing antibodies, three different dilutions of an unknown blood serum sample are compared with three similar dilutions of a control or known sample. In this procedure, the ring diameters of the control samples can be compared to the ring diameters of the unknown samples and the complement fixing antibody titer thereby estimated. The zone of lysis is substantially inversely proportional to the degree of complement fixed by the reaction.
Example 1 is repeated except that ;Rocky Mountain spotted fever antigen is substituted for the Kolmer antigen in said example to determine the complement fixing antibody titer of a blood serum sample against the test antigen. , ; .
Example 3 Example 1 is repeat ed except that epidemic typhus antigen is_ substituted for the Kolmer antigen in said example to determine the complement fixing antibody titer of a blood serum sample against the test antigen.
Example 4 Example 1 is repeated except that mumps virus antigen is substituted for the Kolmer antigen in said example to determine the complement fixing antibody titer of a blood serum sample against the test antigen.
Example 5 Example 1 is repeated except that coccidioidomycosis fungal antigen is substituted for the Kolmer antigen in said example to determine the complement fixing antibody titer of a blood serum sample against the test antigen.
Various other examples can be devised by the person skilled in the art after reading the foregoing specification and the appended claims without departing from the spirit and: scope of the invention heroin. Thus, other known complement fixing antigens can be sub- I stituted for the antigens in the above examples for the determination of the corresponding complement fixing antibodies. Other dilutions of antigen, complement, hemolysin-sensitized erythrocytes and gelling agent can be used in place of the specific dilutions described in the foregoing examples with substantially equivalent results. All such further examples are within the scope of this invention as defined in the appended claims.
Claims (11)
1. A method for the determination of complement fixing antibodies in biological fluids comprising admixing predetermined amounts of complement and complement fixing antigen corresponding to the antibody to be determined with an antibody-containing biological fluid in predetermined proportions and then reacting the mixture with hemolysin-sensitized erythrocytes which are suspended in a known concentration in a semi-solid gel medium*
2. A method according to Claim 1 in which the gel medium containing the hemolysin-sensitized erythrocytes is on a plate and in which the mixture of complement, complement fixing antigen and antibody-containing biological fluid is allowed to come into contact with said hemolysin-sensitized erythrocytes for reaction therewith by diffusion of the mixture from a well in the surface of the gel.
3. · A method according to Claim 1 or 2 in which the gel medium contains from .i0.1# to 5$ by weight agar.
4. A method according to any of the preceding Claims, in which the gel medium contains from 0.05$ to 5$ weight hemolysin-sensitized erythrocytes.
5. A method according to any of the preceding Claims, in which the complement, complement fixing antigen, and antibody-containing biological fluid are mixed in approximately equal proportions by volume.
6. A method accordin to any of the preceding Claims, wherein the complement fixing antibodies are determined in blood serum. 34930/2
7. A method for the determination of complement fixing antibodies in biological fluids substantially as described in the Example.
8. An agar gel plate for the determination of complement fixing antibodies comprising a plate carrying an agar-gel medium containing hemolysin sensitized erythrocytes.
9. * . An agar-gel plate according to Claim 8 in which the agar-gel medium comprises from 0.1 to 55¾ by weight of agar.
10. ,. An agar-gel plate according to Claim 8 or 9 in which the agar-gel medium contains from 0.05 to 5$ by weight of hemolysin^sensitized erythrocytes.
11. An agar-gel plate for the determination of complement fixing antibodies in biological fluids substantially as described in the Example, For the Applicants ND/ru
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84833869A | 1969-08-07 | 1969-08-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL34930A0 IL34930A0 (en) | 1970-09-17 |
| IL34930A true IL34930A (en) | 1973-06-29 |
Family
ID=25303007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL34930A IL34930A (en) | 1969-08-07 | 1970-07-15 | Haemolytic assay system |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS5022086B1 (en) |
| CA (1) | CA937499A (en) |
| ES (1) | ES382558A1 (en) |
| IL (1) | IL34930A (en) |
-
1970
- 1970-07-15 CA CA088272A patent/CA937499A/en not_active Expired
- 1970-07-15 IL IL34930A patent/IL34930A/en unknown
- 1970-08-07 ES ES382558A patent/ES382558A1/en not_active Expired
- 1970-08-07 JP JP6873570A patent/JPS5022086B1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL34930A0 (en) | 1970-09-17 |
| ES382558A1 (en) | 1973-05-01 |
| CA937499A (en) | 1973-11-27 |
| JPS5022086B1 (en) | 1975-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3951748A (en) | Sensitized matrix for detection of disease | |
| US4060597A (en) | Serological reagent and preparation thereof | |
| Takahashi et al. | Duality of hepatitis B e antigen in serum of persons infected with hepatitis B virus: evidence for the nonidentity of e antigen with immunoglobulins. | |
| US3843777A (en) | Hemolytic assay system | |
| EP0070278B1 (en) | A method of diagnosis | |
| DK150810B (en) | PROCEDURE FOR DETERMINING ONE OR MORE ANTIGENS IN A TEST WITH ANIMALS BONDED FOR SMALL PARTICLES | |
| FI63493C (en) | PAIDISANDE AV HEPATITIS B YTANTIGEN GENOM LATEX AGGLUTINATION | |
| SCHMIDT | Solid-phase hemadsorption: a method for rapid detection of Treponema pallidum-specific IgM | |
| FI60319B (en) | FOERFARANDE FOER PAOVISNING ELLER BESTAEMNING AV ANTIKROPPAR I KROPPSVAETSKOR MED HJAELP AV KAENDA ANTIGENER ELLER FOER BESTTAEMNING AV ANTIGENER MED HJAELP AV KAENDA ANTIKROPPAR FRAON KROPPSVAETSKOR SAMT MED | |
| US4753893A (en) | Method and article for detection of immune complexes | |
| Tovey et al. | Enhanced immunodetection of blotted house dust mite protein allergens on nitrocellulose following blocking with Tween 20 | |
| IL34930A (en) | Haemolytic assay system | |
| JP2661664B2 (en) | Latex agglutination method and agglutination reagent for detecting anti-streptococcus DNase B | |
| JPS60177265A (en) | Antibody immunoglobulin class detection method | |
| JP3618797B2 (en) | Immunoassay | |
| US4013411A (en) | Method for detecting hepatitis associated antigen | |
| US3887697A (en) | Hemagglutination method for australia antigen and antibody thereto | |
| Forger 3rd et al. | Single-radial hemolysis as a cost-effective determinant of rubella antibody status | |
| Sato et al. | Treponema pallidum specific IgM haemagglutination test for serodiagnosis of syphilis. | |
| EP0049161B1 (en) | Method for preparing sample for use in endotoxin test and kit for preparing said sample | |
| Merrill et al. | Quantitation of the hepatitis-associated antigen by electroimmunodiffusion | |
| US3697639A (en) | Serological test for the detection of hepatitis | |
| US3783103A (en) | Thrombin assay system | |
| Thulstrup et al. | Screening for hepatitis associated antigen by three different methods | |
| Wicher et al. | Studies of rabbit testes infected with Treponema pallidum. II Local synthesis of antibodies. |